Overview
TVRD market data
Price History
TVRD price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$46.60 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.34 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $1.50 – $43.65 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $20.1 · P/B 1.93 · P/S 5.64.
Company News
BTIG Maintains Buy on Tvardi Therapeutics, Lowers Price Target to $5Benzinga · Jul 30, 2026, 7:04 PM
Tvardi Therapeutics Selects Ulcerative Colitis As Initial Indication For TTI-109, Says Phase 1 Showed Up To 76% Reduction In Th17 Subsets; Trial Planned For 2027Benzinga · Jul 30, 2026, 11:34 AM
8-K filing — Tvardi Therapeutics, Inc. (TVRD)SEC EDGAR · Jul 30, 2026, 11:30 AM
Tvardi Therapeutics Increases At-The-Market Offering Program To $9.69M In SharesBenzinga · Jul 17, 2026, 8:35 PM
Why Is Tvardi Therapeutics Stock Falling Thursday?Benzinga · Jul 9, 2026, 1:10 PM
Tvardi Therapeutics Shares Halted On Circuit Breaker To The Upside, Stock Now Up 79.35%Benzinga · Jul 8, 2026, 7:45 PM
Why Is Tvardi Therapeutics Stock Gaining Tuesday?Benzinga · Jul 7, 2026, 5:55 PM
BTIG Reiterates Buy on Tvardi Therapeutics, Maintains $15 Price TargetBenzinga · Jul 7, 2026, 5:05 PM
Tvardi Therapeutics Announces Phase 1 Results For TTI-109, Next-Gen STAT3 Inhibitor; Co. Plans To Advance TTI-109 Into STAT3-Driven Dermatologic And Gastrointestinal Diseases, Subject To Additional FundingBenzinga · Jul 7, 2026, 11:25 AM
Why Universe Pharmaceuticals Shares Are Trading Higher By Around 228%; Here Are 20 Stocks Moving PremarketBenzinga · Jun 29, 2026, 11:05 AM